Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Blueprint Medicines Corp (NQ: BPMC )

46.71 -1.07 (-2.24%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 327,752
Open 47.54
Bid (Size) 43.00 (1)
Ask (Size) 48.84 (1)
Prev. Close 47.78
Today's Range 46.29 - 48.26
52wk Range 40.78 - 85.67
Shares Outstanding 59,830,611
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Analyst Ratings for Blueprint Medicines
 
Via Benzinga
Blueprint Medicines's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q3, Blueprint Medicines's (NASDAQ:BPMC) reported sales totaled $65.98 million. Despite a 16.62% increase in earnings, the company posted a loss of $133.16... 
Via Benzinga

Performance

YTD
+7.88%
+7.88%
1 Month
+6.62%
+6.62%
3 Month
-9.90%
-9.90%
6 Month
-7.69%
-7.69%
1 Year
-39.42%
-39.42%

More News

Read More
Blueprint Medicines Stock Gets Price Target Cut Amid Lower Than Expected Ayvakit Uptake
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 2, 2022
Via Benzinga
9 Analysts Have This to Say About Blueprint Medicines
Via Benzinga
Recap: Blueprint Medicines Q3 Earnings
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
Via Benzinga
Where Blueprint Medicines Stands With Analysts
Via Benzinga
Blueprint Medicines' Ayvakit 'Will Garner Approval' Despite Questions, This Analyst Says
Via Benzinga
Uber To Rally Around 82%? Here Are 5 Other Price Target Changes For Wednesday
Via Benzinga
NASDAQ:BPMC Investor Notice: Investigation over Potential Wrongdoing at Blueprint Medicines Corporation
Via SBWire
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Via Benzinga
Analyst Sees Deteriorated Treatment Effect Of Blueprint's Much Awaited Mastocytosis Data
Via Benzinga
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation - BPMC
Via NewMediaWire
Blueprint Medicines Corporation (NASDAQ:BPMC) Investor Notice: Investigation over Possible Violations of Securities Laws
Via SBWire
What 14 Analyst Ratings Have To Say About Blueprint Medicines
Via Benzinga
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Why GigaCloud Technology Jumped 206%; Here Are 79 Biggest Movers From Yesterday
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Blueprint Medicines Corporation with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
This Healthcare Stock Dipped Over 30%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
EQUITY ALERT: Rosen Law Firm Encourages Blueprint Medicines Corporation Investors to Inquire About Class Action Investigation – BPMC
From Rosen Law Firm
Via Business Wire
Sanofi, Children's Place And Some Other Big Stocks Moving Lower On Wednesday
Via Benzinga
Why Blue Water Vaccines Is Trading Higher By Around 80%, Here Are 61 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.